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Abstract
The tumorigenesis of pituitary adenomas is poorly understood. Mutations of the PIK3CA proto-oncogene, which encodes the 
p110-α catalytic subunit of PI3K, have been reported in various types of human cancers regarding the role of the gene in cell 
proliferation and survival through activation of the PI3K/Akt signaling pathway. Only one Chinese study described somatic 
mutations and amplification of the PIK3CA gene in a large series of pituitary adenomas. The aim of the present study was 
to determine genetic alterations of PIK3CA in a second series that consisted of 33 pituitary adenomas of different subtypes 
diagnosed by immunohistochemistry: 6 adrenocorticotropic hormone-secreting microadenomas, 5 growth hormone-secreting 
macroadenomas, 7 prolactin-secreting macroadenomas, and 15 nonfunctioning macroadenomas. Direct sequencing of exons 
9 and 20 assessed by qPCR was employed to investigate the presence of mutations and genomic amplification defined as 
a copy number ≥4. Previously identified PIK3CA mutations (exon 20) were detected in four cases (12.1%). Interestingly, the 
Chinese study reported mutations only in invasive tumors, while we found a PIK3CA mutation in one noninvasive corticotroph 
microadenoma. PIK3CA amplification was observed in 21.2% (7/33) of the cases. This study demonstrates the presence of 
somatic mutations and amplifications of the PIK3CA gene in a second series of pituitary adenomas, corroborating the previously 
described involvement of the PI3K/Akt signaling pathway in the tumorigenic process of this gland.
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The tumorigenesis of pituitary adenomas is poorly 
understood. The phosphatidylinositol 3-kinases (PI3Ks) 
are a group of heterodimeric lipid kinases composed of 
regulatory (85-kDa; p85) and catalytic (110-kDa; p110) 
subunits that play a key role in cell growth, proliferation, 
motility, and survival (1-3). The activation of PI3K results 
in phosphorylation of phosphatidylinositol-4,5-biphosphate 
(PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3), 
which acts as an anchor for Akt serine/threonine kinase and 
3-phosphoinositide-dependent protein kinase-1 (PDK1), 
and facilitates phosphorylation of Akt by PDK1, stimulat-
ing Akt activity and subsequent phosphorylation of several 
proteins involved in a variety of intracellular processes, 
including antiapoptosis (4,5). PIP3 levels are tightly regu-
lated by the action of phosphatases such as phosphatase 
and tensin homologue (PTEN) (6).
Mutations of the PIK3CA proto-oncogene, which en-
codes the p110-α catalytic subunit of PI3K, have been 
reported in various types of human cancers (7-10) and 
more than 80% of PIK3CA mutations are clustered in the 
helical domain encoded by exon 9 and in the kinase domain 
encoded by exon 20 (11), as shown with high prevalence 
in endometrioid, esophageal and pancreatic carcinomas 
(12-15).
A recent Chinese study (16) has described somatic 
mutations and amplifications of the PIK3CA gene in a 
large series of pituitary adenomas, implicating the PI3K/
Akt signaling pathway in the tumorigenic process of this 
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gland. Since a diversity of mutational spectra in different 
populations had been described for certain neoplasias 
(17,18), in the present study we investigated genetic altera-
tions in the PIK3CA proto-oncogene in a second series of 
pituitary adenomas.
Material and Methods
Tissue specimens and DNA isolation
Tissue collection was carried out in compliance with 
the Institutional Ethics Committee (CAPPesq) and in ac-
cordance to the Declaration of Helsinki, with informed and 
free written consent being required from each subject or 
subject’s guardian. From 1994-2009, tumor tissues were 
obtained from patients diagnosed with pituitary adenomas. 
During surgery, tumor fragments were collected into sterile 
containers and immediately frozen in liquid nitrogen. Thirty-
three sporadic pituitary adenomas were obtained after 
surgery. The anatomo-pathological characteristics of these 
adenomas are shown in Table 1. Pituitary adenomas con-
sisted of 6 adrenocorticotropic hormone (ACTH)-secreting 
microadenomas, 5 growth hormone (GH)-secreting mac-
roadenomas, 7 prolactin (PRL)-secreting macroadenomas, 
and 15 nonfunctioning (NF) macroadenomas. As control, 
four normal pituitary tissues were obtained within 8 h post 
mortem from subjects without endocrine diseases. The 
tissue fragments were fragmented in a tissue pulverizer 
(Mikro-Dismembrator U, B. Braun Melsungen, Germany). 
Tumor DNA was extracted using the DNeasy kit (Qiagen, 
USA) according to manufacturer instructions.
Mutation analysis
Exons 9 and 20 of PIK3CA were analyzed by direct 
sequencing on an ABI 3130X Genetic Analyzer (Applied 
Biosystems, USA) after PCR amplification of genomic DNA. 
PCR was carried out in 50 µL containing 100 ng genomic DNA, 
0.2 mM of each primer, 200 µM deoxynucleotides, 1X buffer 
and 1 U DNA Taq polymerase (GE Healthcare, USA). The 
nucleotide sequences for the primers were designed using 
the Primer3 software: exon 9 forward 5’-CAAAGCAATTTCT 
ACACGAGATCC-3’; exon 9 reverse 5’-GTAAAAACATGCTG 
AGATCAGCCACAT-3’; exon 20 forward 5’-TGGAATGCC 
AGAACTACAATCTTT-3’, and exon 
20 reverse 5’-GGTCTTTGCCTGCTG 
AGAGTT-3’ (Invitrogen, USA). Reac-
tions were carried out under the following 
cycling conditions: 95°C for 5 min, 35 
cycles of 95°C for 30 s, followed by 56°C 
(exon 9) or 62°C (exon 20) for 30 s and 
72°C for 10 min. The PCR products were 
subjected to direct sequencing with the 
use of BigDye Terminator sequencing 
reagents (Applied Biosystems) with the 
following cycles: 96°C for 15 s, 50°C for 
15 s and 60°C for 4 min for 35 cycles. All 
mutated DNA sequences were confirmed by sequencing in 
the reverse direction.
Copy number analysis
PIK3CA gene copy number amplification was assessed 
by qPCR using Platinum SYBR Green qPCR SuperMix-
UDG (Invitrogen), 100 ng DNA and primers for genomic 
sequences (PIK3CA forward: 5’-ATCTTTTCTCAATGATGC 
TTGGCT-3’ and PIK3CA reverse: 5’-CTAGGGTGTTTCG 
AATGTATG-3’) and compared with the signal obtained from 
COL7A1 as reference gene (COL7A1 forward: 5’-ACC 
CAGTACCGCATCATTGTG-3’ and COL7A1 reverse: 5’-TC 
AGGCTGGAACTTCAGTGTG-3’). 
PCR was carried out on a Rotor-Gene 6000 instrument 
(Corbett Life Science, Australia). The reaction consisted of 
an initial incubation at 95°C for 10 min followed by 40 cycles 
of 95°C for 15 s and 55°C for 1 min. Fluorescence changes 
were monitored after each cycle. Melting curve analysis 
was performed at the end of each reaction to confirm 
PCR product’s identity (72°C ramping to 99°C at 0.2°C/s 
with continuous fluorescence readings). Standard curves 
were constructed to assess the amplification efficiency of 
PIK3CA and COL7A1 using duplicate serial dilutions with 
seven different DNA concentrations (400 to 6.25 ng) from 
a reference sample of DNA obtained from normal pituitary 
tissue. Since equal amplification efficiencies of target and 
reference genes were attained (E >0.9), the mathematical 
model 2-ΔΔCt was used to evaluate the relative genomic 
amplification of PIK3CA. All samples were run in duplicate. 
DNA obtained from a pool of four normal pituitary tissues 
was included in the assay as a calibrator sample and DNA 
extracted from the MCF-7 cell line was used as a positive 
control for PIK3CA amplification. DNA amplification was 
defined as values ≥4 (16).
Results
PIK3CA mutations
Previously reported PIK3CA mutations were detected 
in four cases (12%): 3 of 15 (20%) NF pituitary adenomas 
and 1 of 6 (16.6%) ACTH-secreting tumors, both in exon 
20 (Table 2). No mutations were found in exon 9. 
Table 1. Demographic data and anatomo-pathological findings of 33 patients with 
pituitary adenomas who participated in the present study.
Pituitary adenomas N Gender 
(male/female)
Age (years) Tumor size 
(micro/macroadenoma)
ACTH-secreting  6 4/2 32.3 (13-61) 6/0
GH-secreting  5 2/3 30.2 (23-55) 0/5
PRL-secreting  7 1/6 31 (20-64) 0/7
Nonfunctioning 15 6/9 44 (21-70)  0/15
ACTH = adrenocorticotropic hormone; GH = growth hormone; PRL = prolactin; mi-
croadenoma = ≤10 mm; macroadenoma = ≥10 mm.
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Amplification of PIK3CA
The number of copies of the PIK3CA gene in each 
tumor sample is shown in Figure 1. Genomic amplification 
was observed in 21.2% (7/33) of the cases; in 4 of 5 
(80%) GH-secreting adenomas, 1 of 6 (16.6%) ACTH-
secreting adenomas and in 2 of 15 (13.3%) NF pitu-
Figure 1. PIK3CA gene copy number detected by qPCR in different subtypes of pituitary adenomas. Positive amplification is defined 
as ≥4 copies. ACTH = adrenocorticotropic hormone-secreting adenoma; GH = growth hormone-secreting macroadenoma; PRL = 
prolactin-secreting macroadenoma; NF = nonfunctioning pituitary adenoma.
Table 2. PIK3CA mutations found in four pituitary adenomas.
Exon Functional domain PIK3CA DNA mutation Amino acid Subtype of tumor
20 Kinase domain GCC > GAC, C2994A Ala995Asp, A > D ACTH
20 Kinase domain GGC > GGT, C3031T Gly1007Gly, G > G NF
20 Kinase domain TCT > CCT, T3053C Ser1015Pro, S > P NF
20 Kinase domain CAA > CGA, A3108G Gln1033Arg, Q > R NF
ACTH = adrenocorticotropic hormone-secreting adenoma; NF = nonfunctioning pituitary ad-
enoma.
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itary adenomas. No genomic amplification was detected 
in PRL-secreting adenomas. 
Discussion
Several studies have implicated PIK3CA somatic muta-
tions and genomic amplification in the tumorigenic process 
of different human cancers (19-26). In the present study, 
we investigated mutations and genomic amplification of the 
PIK3CA proto-oncogene in 33 sporadic pituitary adenomas. 
During our experiments, another group of investigators 
evaluated the association of these genetic alterations in 
pituitary tumors (16). Given the diversity of mutational 
spectra in different populations for certain neoplasias 
(17,18), we decided to continue to examine the incidence 
of these mutations and amplifications in pituitary tumors 
of Brazilian patients.
The overall frequency of PIK3CA gene mutations and 
amplification in the Chinese study of 353 pituitary tumors 
was 2.3% (8.8% of the invasive tumors and 0% of the non-
invasive ones) and 28% (26.3% of the noninvasive tumors 
and 32.9% of the invasive ones), respectively (16), while in 
the current series, PIK3CA mutations and amplification were 
found in 12.1 and 21.2% of the cases, respectively. 
Although it is difficult to compare studies that differ so 
much in the size of the evaluated population, the present 
study corroborates the previous report (16) that genetic 
alterations in the PIK3CA gene are found in pituitary tu-
mors. We only detected mutations in one ACTH-secreting 
and three NF pituitary adenomas, while Lin et al. (16) also 
found mutations in two PRL-secreting tumors. Mutations in 
GH-secreting tumors were not found in any of the two series. 
Interestingly, the Chinese study reported mutations only in 
invasive tumors, while we found a PIK3CA mutation in one 
noninvasive corticotroph microadenoma. Recent reports 
have shown that PIK3CA knockdown reduces proliferation 
and invasiveness in different cell lines (27-29). 
Defining positive gene amplification as a copy number 
≥4, ACTH-secreting tumors (16.6%), NF pituitary tumors 
(13.3%) and particularly GH-secreting tumors (80%) were 
identified as harboring PIK3CA amplifications, with the 
highest number being 14 copies in a GH-secreting tumor. 
Adding to the previous Chinese study, PIK3CA amplification 
was more common than mutations. Amplification of PIK3CA 
has been demonstrated to be a mechanism of resistance 
for PI3K-targeted therapy in cancer (30).
The coexistence of PIK3CA mutations with amplifica-
tions in pituitary adenomas seems to be rare; only one case 
(NF tumor) harbored coexisting PIK3CA copy gain and a 
gene mutation. These findings suggest that PIK3CA muta-
tion and amplification are independent oncogenic pathways 
in pituitary tumors (16), as mutually exclusive mechanisms, 
as already described for thyroid tumors (31); however, the 
coexistence of these genetic alterations has been reported 
in breast cancers (32).
The major effector of PI3K is Akt kinase, which phospho-
rylates target proteins regulating key processes such as cell 
proliferation and survival. This process is counteracted by 
the phosphatase encoded by the PTEN tumor suppressor 
gene, which opposes PI3K activity (33). A recent study has 
implicated phosphorylated Akt expression associated with 
PIK3CA mutations in low-stage colorectal cancers (34). 
In 2005, Musat et al. (6) reported a higher expression of 
phosphorylated Akt in pituitary tumors in comparison to the 
normal gland in the absence of PTEN mutations. Thus, it is 
reasonable to suppose that increased Akt phosphorylation in 
pituitary adenomas could result from activation of the PI3K 
pathway following PIK3CA mutation or amplification.
In summary, this study demonstrates the presence of 
somatic mutations and amplifications of the PIK3CA gene 
in a second series of pituitary adenomas, corroborating the 
previously described involvement of the PI3K/Akt signaling 
pathway in the tumorigenesis of this gland (16,35,36) and 
its molecular potential for targeted therapies (3,27-29,37)
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